![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Ketorolac Tromethamine Tablets USP, 10 mg, is a nonsteroidal anti-inflammatory drug (“NSAID”) indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment.
Lead Product(s): Ketorolac Trometamol
Therapeutic Area: Neurology Product Name: Ketorolac Tromethamine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
Under the terms of the Agreement, the royalty rate applicable to U.S. net sales of OMIDRIA (phenylephrine) decreased from 50 percent to 30 percent of U.S. net sales following achievement of the Milestone Event.
Lead Product(s): Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Ophthalmology Product Name: Omidria
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rayner
Deal Size: $1,326 million Upfront Cash: $126.0 million
Deal Type: Divestment February 06, 2023
Details:
Under the Royalty Purchase Agreement, DRI is entitled to royalties on net sales of OMIDRIA (having phenylephrine) received between September 1, 2022 and December 31, 2030, subject to annual caps.
Lead Product(s): Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Neurology Product Name: Omidria
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: DRI Healthcare Acquisitions
Deal Size: $188.4 million Upfront Cash: Undisclosed
Deal Type: Agreement October 03, 2022
Details:
Ketorolac (NTM-001) is a novel, alcohol-free formulation of ketorolac in a convenient, ready-to-use, pre-mixed bag for continuous 24 hours IV infusion, for the treatment of moderately severe acute pain requiring analgesia.
Lead Product(s): Ketorolac Trometamol
Therapeutic Area: Neurology Product Name: NTM-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neumentum
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
The company has entered into a formal agreement with Evolution Research Group (ERG), a leading postsurgical pain clinical research site network in the U.S., to conduct its registration trials with CA-008 (vocacapsaicin).
Lead Product(s): Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area: Neurology Product Name: CA-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Evolution Research Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 02, 2022
Details:
URMC will participate in the vocacapsaicin Phase 3 clinical trials and develop innovative methods to capture vocacapsaicin’s benefit to patient recovery and rehabilitation.
Lead Product(s): Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area: Neurology Product Name: CA-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Rochester Medical Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 02, 2022
Details:
Concentric intends to use the proceeds from the financing to further fund Phase 3 development activities for vocacapsaicin, its lead therapeutic candidate for postsurgical pain.
Lead Product(s): Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area: Neurology Product Name: CA-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 26, 2022
Details:
As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.
Lead Product(s): Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Ophthalmology Product Name: Omidria
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rayner
Deal Size: $1,326 million Upfront Cash: $126.0 million
Deal Type: Divestment December 23, 2021
Details:
As part of the agreement, Rayner will acquire the OMIDRIA commercial organization, including the OMIDRIA sales force. Rayner plans to expand the sales force in both the U.S. and ex-U.S., and further accelerating U.S. market growth of OMIDRIA.
Lead Product(s): Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Omidria
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rayner Surgical Group Limited
Deal Size: $1,000.0 million Upfront Cash: $125.0 million
Deal Type: Agreement December 02, 2021
Details:
As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.
Lead Product(s): Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Ophthalmology Product Name: Omidria
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rayner
Deal Size: $1,325 million Upfront Cash: $125.0 million
Deal Type: Divestment December 02, 2021
Details:
Nemera's multidose eye dropper Novelia® has been approved by ANVISA for the preservative-free formulations CLILON (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug that is used to treat moderately severe pain and inflammation, usually after surgery.
Lead Product(s): Ketorolac Trometamol
Therapeutic Area: Ophthalmology Product Name: Clilon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ache Laboratorios Farmaceuticos SA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
The data to be presented include the final study results from four cohorts of a randomized, controlled clinical trial evaluating NTM-001, a novel, alcohol-free 24-hour continuous infusion formulation of the well-established potent NSAID analgesic ketorolac tromethamine.
Lead Product(s): Ketorolac Trometamol
Therapeutic Area: Neurology Product Name: NTM-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
The licensing agreement provides Nuance with the exclusive rights to develop and commercialize Neumentum’s novel ketorolac for IV infusion (NTM-001) in China.
Lead Product(s): Ketorolac Trometamol
Therapeutic Area: Neurology Product Name: NTM-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nuance Biotech
Deal Size: $53.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement October 21, 2020
Details:
OX338 demonstrated improved bioavailability and tolerability compared to commercially available reference product.
Lead Product(s): Ketorolac Trometamol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020